Literature DB >> 10321955

In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation.

D D Eckels1, N Tabatabail, T H Bian, H Wang, S S Muheisen, C M Rice, K Yoshizawa, J Gill.   

Abstract

Hepatitis C Virus (HCV) causes chronic infection in 80-90% of those exposed and persists despite evidence of immune recognition. To understand the immunological basis of this phenomenon, we have synthesized a non structural (NS) protein that is critical to HCV infection and replication, NS3, and used it to study in vitro helper T-cell responses from infected individuals. Strong proliferative responses were generated by peripheral T-cells isolated from a subset of chronically infected patients, but not by normal, non-infected controls. Interestingly, though gamma-interferon (gammaIfn) and IL-10 were both secreted in response to stimulation by NS3 antigen, IL-2 was not. In contrast, IL-2 was secreted in response to influenza virus vaccine antigen. Lack of IL-2 induction was confirmed by a failure to amplify IL-2 mRNA upon NS3 antigen stimulation, whereas IL-4, IL-15, and gammaIfn mRNA were seen as early as 24 h. The predominance of IL-4 and IL-10 and the lack of IL-2 suggests that in vitro responses to at least some HCV antigens are biased towards a Th2 phenotype, which may be conducive to viral persistence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10321955     DOI: 10.1016/s0198-8859(98)00111-6

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  14 in total

1.  Kinetics of soluble tumour necrosis factor (TNF)-alpha receptors and cytokines in the early phase of treatment for chronic hepatitis C: comparison between interferon (IFN)-alpha alone, IFN-alpha plus amantadine or plus ribavirin.

Authors:  F Torre; S Rossol; N Pelli; M Basso; A Delfino; A Picciotto
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

2.  Mechanism of action of ribavirin in the treatment of chronic hepatitis C.

Authors:  Helen S Te; Glenn Randall; Donald M Jensen
Journal:  Gastroenterol Hepatol (N Y)       Date:  2007-03

3.  Naturally occurring CD4+ T-cell epitope variants act as altered peptide ligands leading to impaired helper T-cell responses in hepatitis C virus infection.

Authors:  Matthew F Cusick; Meiying Yang; Joan C Gill; David D Eckels
Journal:  Hum Immunol       Date:  2011-03-04       Impact factor: 2.850

4.  Hepatitis C virus core protein induces an anergic state characterized by decreased interleukin-2 production and perturbation of mitogen-activated protein kinase responses.

Authors:  Sara Sundström; Seisuke Ota; Lina Y Dimberg; Maria G Masucci; Anders Bergqvist
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

5.  Cytokine serum levels in patients with chronic HCV infection.

Authors:  Nick E Spanakis; George A Garinis; Evangelos C Alexopoulos; George P Patrinos; Panayotis G Menounos; Alexandra Sklavounou; Evangelos N Manolis; Vassilis G Gorgoulis; Dimitrios Valis
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

6.  Polymorphisms of some cytokines and chronic hepatitis B and C virus infection.

Authors:  Qiu-Ju Gao; Dian-Wu Liu; Shi-Yong Zhang; Min Jia; Li-Min Wang; Li-Hong Wu; Shu-Yun Wang; Li-Xin Tong
Journal:  World J Gastroenterol       Date:  2009-11-28       Impact factor: 5.742

7.  CD4+ T-cell engagement by both wild-type and variant HCV peptides modulates the conversion of viral clearing helper T cells to Tregs.

Authors:  Matthew F Cusick; Jane E Libbey; Joan Cox Gill; Robert S Fujinami; David D Eckels
Journal:  Future Virol       Date:  2013-07       Impact factor: 1.831

8.  Hepatitis C virus core protein leads to immune suppression and liver damage in a transgenic murine model.

Authors:  Carolina Soguero; Myungsoo Joo; Kimberly A Chianese-Bullock; Duong Tony Nguyen; Kenneth Tung; Young S Hahn
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

9.  Lower th-1/th-2 ratio before interferon therapy may favor long-term virological responses in patients with chronic hepatitis C.

Authors:  Naohiko Masaki; Sugano Fukushima; Shigeki Hayashi
Journal:  Dig Dis Sci       Date:  2002-10       Impact factor: 3.199

10.  In vitro antigen-specific induction of IL-22 in human subjects that resolved HCV infection.

Authors:  Matthew F Cusick; Jane E Libbey; Robert S Fujinami; David D Eckels
Journal:  Future Virol       Date:  2012-07-01       Impact factor: 1.831

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.